mitoxantrone has been researched along with Pancytopenia in 9 studies
Mitoxantrone: An anthracenedione-derived antineoplastic agent.
mitoxantrone : A dihydroxyanthraquinone that is 1,4-dihydroxy-9,10-anthraquinone which is substituted by 6-hydroxy-1,4-diazahexyl groups at positions 5 and 8.
Pancytopenia: Deficiency of all three cell elements of the blood, erythrocytes, leukocytes and platelets.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The efficacy and toxicity of carboplatin plus mitoxantrone in blast crisis of chronic myeloid leukemia (CMLBC) were evaluated." | 9.14 | A pilot study of carboplatin and mitoxantrone in blast crisis of chronic myeloid leukemia. ( Dutcher, JP; Gaynor, B; Morris, EL; Paietta, E; Wiernik, PH, 2010) |
| "The efficacy and toxicity of carboplatin plus mitoxantrone in blast crisis of chronic myeloid leukemia (CMLBC) were evaluated." | 5.14 | A pilot study of carboplatin and mitoxantrone in blast crisis of chronic myeloid leukemia. ( Dutcher, JP; Gaynor, B; Morris, EL; Paietta, E; Wiernik, PH, 2010) |
| " From August 1998 to December 2000 2-CdA was administered at a dosage of 0." | 2.70 | Cladribine combined with cyclophosphamide and mitoxantrone as front-line therapy in chronic lymphocytic leukemia. ( Boguradzki, P; Błoński, JZ; Calbecka, M; Ceglarek, B; Dmoszyńska, A; Dwilewicz-Trojaczek, J; Góra-Tybor, I; Kasznicki, M; Konopka, L; Kuliczkowski, K; Moskwa-Sroka, B; Nowak, W; Robak, T; Skotnicki, AB; Stella-Hołowiecka, B; Sułek, J; Wołowiec, D, 2001) |
| "To determine optimal dosage, Dihydroxyanthracenedione (DHAD) was given once daily for 3 days at dosage levels of 6, 7, 8, and 10 mg/m2 in combination with a 7-day continuous infusion of cytosine arabinoside (Ara-C)." | 1.27 | Toxicity evaluation of dihydroxyanthracenedione (DHAD) in combination with cytosine arabinoside (Ara-C). ( Civin, CI; Krischer, J; Land, VJ; Ragab, AH; Steuber, CP; Vietti, TJ, 1987) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (11.11) | 18.7374 |
| 1990's | 3 (33.33) | 18.2507 |
| 2000's | 4 (44.44) | 29.6817 |
| 2010's | 1 (11.11) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Dutcher, JP | 1 |
| Morris, EL | 1 |
| Gaynor, B | 1 |
| Paietta, E | 2 |
| Wiernik, PH | 1 |
| Jehn, U | 1 |
| Suciu, S | 1 |
| Thomas, X | 1 |
| Lefrère, F | 1 |
| Muus, P | 1 |
| Berneman, Z | 1 |
| Marie, JP | 1 |
| Adamo, F | 1 |
| Fillet, G | 1 |
| Nobile, F | 1 |
| Ricciuti, F | 1 |
| Leone, G | 1 |
| Rizzoli, V | 1 |
| Montanaro, M | 1 |
| Beeldens, F | 1 |
| Fazi, P | 1 |
| Mandelli, F | 1 |
| Willemze, R | 1 |
| de Witte, T | 1 |
| Amadori, S | 1 |
| Huang, XJ | 1 |
| Liu, DH | 1 |
| Liu, KY | 1 |
| Xu, LP | 1 |
| Chen, H | 1 |
| Han, W | 1 |
| Tzavara, V | 1 |
| Stamoulis, K | 1 |
| Aroni, KG | 1 |
| Kordossis, T | 1 |
| Boki, KA | 1 |
| Navarro, JT | 1 |
| Hernández, JA | 1 |
| Ribera, JM | 1 |
| Sancho, JM | 1 |
| Oriol, A | 1 |
| Pujol, M | 1 |
| Millá, F | 1 |
| Feliu, E | 1 |
| Bennett, JM | 1 |
| Young, MS | 1 |
| Liesveld, JL | 1 |
| Miller, KB | 1 |
| Lazarus, HM | 1 |
| Marsh, RD | 1 |
| Friedenberg, WR | 1 |
| Saba, HT | 1 |
| Hayes, FA | 1 |
| Dewald, GW | 1 |
| Hiddemann, W | 1 |
| Rowe, JM | 1 |
| Robak, T | 1 |
| Błoński, JZ | 1 |
| Kasznicki, M | 1 |
| Góra-Tybor, I | 1 |
| Dwilewicz-Trojaczek, J | 1 |
| Boguradzki, P | 1 |
| Konopka, L | 1 |
| Ceglarek, B | 1 |
| Sułek, J | 1 |
| Kuliczkowski, K | 1 |
| Wołowiec, D | 1 |
| Stella-Hołowiecka, B | 1 |
| Skotnicki, AB | 1 |
| Nowak, W | 1 |
| Moskwa-Sroka, B | 1 |
| Dmoszyńska, A | 1 |
| Calbecka, M | 1 |
| Volkova, MA | 1 |
| Kaletin, GI | 1 |
| Steuber, CP | 1 |
| Land, VJ | 1 |
| Civin, CI | 1 |
| Ragab, AH | 1 |
| Krischer, J | 1 |
| Vietti, TJ | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| RANDOMIZED PHASE III STUDY TO EVALUATE THE VALUE OF rHuG-CSF IN INDUCTION AND OF AN ORAL SCHEDULE AS CONSOLIDATION TREATMENT IN ELDERLY PATIENTS WITH ACUTE MYELOGENOUS LEUMEKIA (AML-13 PROTOCOL)[NCT00002719] | Phase 3 | 500 participants (Anticipated) | Interventional | 1995-12-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
6 trials available for mitoxantrone and Pancytopenia
| Article | Year |
|---|---|
A pilot study of carboplatin and mitoxantrone in blast crisis of chronic myeloid leukemia.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Blast Crisis; Carboplatin; Female; Foll | 2010 |
Non-infusional vs intravenous consolidation chemotherapy in elderly patients with acute myeloid leukemia: final results of the EORTC-GIMEMA AML-13 randomized phase III trial.
Topics: Acute Disease; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents; Anti | 2006 |
Donor lymphocyte infusion for the treatment of leukemia relapse after HLA-mismatched/haploidentical T-cell-replete hematopoietic stem cell transplantation.
Topics: Adolescent; Adult; Antineoplastic Agents; Benzamides; Child; Combined Modality Therapy; Cytarabine; | 2007 |
Phase II study of combination human recombinant GM-CSF with intermediate-dose cytarabine and mitoxantrone chemotherapy in patients with high-risk myelodysplastic syndromes (RAEB, RAEBT, and CMML): an Eastern Cooperative Oncology Group Study.
Topics: Aged; Anemia, Refractory, with Excess of Blasts; Antineoplastic Combined Chemotherapy Protocols; Bon | 2001 |
Cladribine combined with cyclophosphamide and mitoxantrone as front-line therapy in chronic lymphocytic leukemia.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cause of Death; Cladribine; Cohort Stud | 2001 |
[The first Russian trial of treating patients with acute nonlymphoblastic leukemias with novantrone combined with cytosar].
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Drug Tolerance; Femal | 1992 |
3 other studies available for mitoxantrone and Pancytopenia
| Article | Year |
|---|---|
Facial heliotrope rash as the initial manifestation of acute myelomonocytic leukemia.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Arthritis; Bo | 1997 |
Prophylactic platelet transfusion threshold during therapy for adult acute myeloid leukemia: 10,000/microL versus 20,000/microL.
Topics: Acute Disease; Adolescent; Adult; Aged; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; C | 1998 |
Toxicity evaluation of dihydroxyanthracenedione (DHAD) in combination with cytosine arabinoside (Ara-C).
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cytarabine; Hea | 1987 |